Ahmed Gaber, MD
Transplant Surgery · Houston, TXNPI 1073579835
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.6%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Sanofi-aventis U.S. LLC at 56.0% of the total. Reporting peaked in 2024 at $19,812 and has fallen 99.8% since, to $47 in 2025. Among transplant surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 19 payments — averaging $1862.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$20K
- Veloxis Pharmaceuticals, Inc.$5K
- Argenx US, Inc.$4K
- Transmedics, Inc.$3K
- Sanofi US Services Inc.$3K
- Sanofi$162
- plus $122 from 3 others
Across 74 payments — averaging $9917.26 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$205K
- Novartis$150K
- Veloxis Pharmaceuticals, Inc.$117K
- Shire North American Group Inc$72K
- CSL Behring$71K
- Sanofi-aventis U.S. LLC$66K
- plus $53K from 2 others
What the payments were for
- Consulting fees$11,93834%
- Speaking & faculty fees$14,37841%
- Travel & lodging$8,60624%
- Food & beverage$4591%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 5 | $19,812 |
| Veloxis Pharmaceuticals, Inc. | 1 | $5,250 |
| Argenx US, Inc. | 1 | $3,900 |
| Transmedics, Inc. | 1 | $3,347 |
| Sanofi US Services Inc. | 2 | $2,788 |
| Sanofi | 3 | $162 |
| AstraZeneca(2 entities) | 4 | $77 |
| Abbott | 1 | $28 |
| Intra-sana Laboratories | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REZUROCK$19,812
- Envarsus$5,250
- ORGAN CARE SYSTEM$3,347
- THYMOGLOBULIN$125
How this compares
$35,381 in reported general payments places this provider in the 90th percentile of 70 transplant surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Houston
- Rafik GhobrialHouston$144K
- Constance MobleyHouston$56K
- David HallHouston$43K
- Nhu Thao GalvanHouston$22K
- Abbas RanaHouston$11K
- Chun-Sing HuangHouston$10K
- Charles VanburenHouston$9K
- John GossHouston$3K
- John BynonHouston$1K
- Rupak KulkarniHouston$253
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.